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Given the central role of genetic factors in the pathogenesis of common neurodegenerative disorders, it is critical that mech-
anistic studies in human tissue are interpreted in a genetically enlightened context. To address this, we performed exome
sequencing and copy number variant analysis on 1511 frozen human brains with a diagnosis of Alzheimer’s disease
(AD, n = 289), frontotemporal dementia/amyotrophic lateral sclerosis (FTD/ALS, n= 252), Creutzfeldt-Jakob disease
(CJD, n= 239), Parkinson’s disease (PD, n = 39), dementia with Lewy bodies (DLB, n= 58), other neurodegenerative, vascu-
lar, or neurogenetic disorders (n = 266), and controls with no significant neuropathology (n = 368). Genomic DNAwas ex-
tracted from brain tissue in all cases before exome sequencing (Illumina Nextera 62 Mb capture) with variants called by
FreeBayes; copy number variant (CNV) analysis (Illumina HumanOmniExpress-12 BeadChip); C9orf72 repeat expansion
detection; and APOE genotyping. Established or likely pathogenic heterozygous, compound heterozygous, or homozygous
variants, together with the C9orf72 hexanucleotide repeat expansions and a copy number gain of APP, were found in 61
brains. In addition to known risk alleles in 349 brains (23.9% of 1461 undergoing exome sequencing), we saw an association
between rare variants in GRN and DLB. Rare CNVs were found in <1.5% of brains, including copy number gains of PRPH that
were overrepresented in AD. Clinical, pathological, and genetic data are available, enabling the retrieval of specific frozen
brains through the UKMedical Research Council Brain Banks Network. This allows direct access to pathological and control
human brain tissue based on an individual’s genetic architecture, thus enabling the functional validation of known genetic
risk factors and potentially pathogenic alleles identified in future studies.
[Supplemental material is available for this article.]
The past 20 years have witnessed major advances in our under-
standing of the genetic landscape of common neurodegenerative
disorders including Alzheimer’s disease (AD), Parkinson’s disease
(PD), motor neuron disease (MND)/amyotrophic lateral sclerosis
(ALS), frontotemporal dementia (FTD), and prion disorders such
as Creutzfeldt-Jakob Disease (CJD). Highly penetrant alleles caus-
ing familial forms of these diseases have now been identified in ap-
proximately 50 genes (Supplemental Methods; for review, see
Mead 2006; Chen et al. 2013; Guerreiro and Hardy 2014; Lin
and Farrer 2014), and both genome-wide association and candi-
date gene studies in sporadic cases have detectednumerous genetic
risk alleles (for review, see Ramanan and Saykin 2013).
The complex genetic architecture of neurodegenerative dis-
eases presents several challenges. First, the implications of a novel
genetic variant are particularly difficult to define (MacArthur et al.
2014). The clinical phenotype often does not correspond to the
anticipated neuropathology, and specific disease alleles are associ-
ated with a wide phenotypic spectrum (Caslake et al. 2008; Grau-
Rivera et al. 2015). This makes it extremely difficult to establish
whether a novel genetic variant is responsible for the disorder—
an issue that is gaining importance, given the widespread use of
clinical exome and genome sequencing.
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Second, our understanding of the functional consequences of
specific mutations is far from clear. This is partly because the ef-
fects of genetic variants can vary between tissue and cell type
(Dimas et al. 2009) and also because several neurodegenerative dis-
eases are modulated by age-related comorbidity. Both factors are
extremely challenging to model in vitro and in animals.
The analysis of postmortem human brain tissue circumvents
some of these difficulties, but understanding the genetic back-
ground is of critical importance. This knowledge enables the strat-
ification of mechanistic studies and the dissection of disease
pathways downstream from specific genetic lesions. It also avoids
the inadvertent enrichment of a study group for specific genetic
disorders, thus preventing results being inappropriately general-
ized across a broad disease category.
To address these issues, we performed exome sequencing and
array-based gene dosage analysis of samples from 1511 frozen
brains from a brain tissue resource: the UK Medical Research
Council Brain Bank. Our analysis provides a genetic compendium
for this accessible tissue resource.
Results
Demographics
The mean age at death across all cases was 68.3 (sd = 17.9) and
ranged from 3 to 103 (Table 1; Supplemental Table S1). Only
2.8%of cases had a family history of disease, as defined by a record-
ed first- or second-degree relative with the same or a related neuro-
degenerative disease (Table 1). The CJD cohort comprised sporadic
(n = 126), variant (n = 62), and other subtypes, as shown
Supplemental Fig S1. All demographic data are available online
(https://ega-archive.org/studies/EGAS00001001599).
Exome sequencing
The mean depth of sequencing of the whole exome was 51.9 (sd
= 12.9), and 49.1 (sd = 13.8) in genes associated with neurode-
generative disease (Supplemental Tables S2, S3). Following qual-
ity control (QC), 1241 brains had data available using all
four genetic approaches (exome sequencing, array single nucleo-
tide variant [SNV] genotyping, C9orf72 PCR, and APOE genotyp-
ing) (Fig. 1; Supplemental Fig. S2).
Single heterozygous SNVs, small insertions, or deletions in genes
known to cause common neurodegenerative diseases
We initially identified rare heterozygous variants present in genes
known to cause autosomal dominant forms of common neurode-
generative diseases (Supplemental Methods; Supplemental Table
S2). In total, 313 variants were seen in 817 cases (Fig. 2), with
261 (83.4%) absent from the 1000 Genomes Project (The 1000
Genomes Project Consortium 2012), 212 (67.7%) absent from
ESP6500 databases (Exome Variant Server 2016), and 149
(47.6%) absent from the ExAC database (Lek et al. 2016). Sixty-
two percent of variants (n = 194) were initially determined to be
of uncertain significance given the lack of any prior available
data, and 39 variants in 57 of the 1461 cases (3.9%) undergoing
exome sequencing were considered to be either pathogenic or like-
ly pathogenic according to the American College of Medical
Genetics criteria for variant pathogenicity (Fig. 2; Richards et al.
2015).
Following comparison and correlation of variants with the
case diagnoses in our data set, 28 pathogenic and likely patho-
genic heterozygous variants were confirmed in 38 cases (3.46%
of 1099 cases of disease) (Fig. 3; Supplemental Table Clinical
data; Supplemental Table Variant data). Importantly, cross-corre-
lating our genomic data with clinical and pathological data en-
abled the reclassification of 149 of the 194 variants that
initially were classified as being of uncertain significance. The ini-
tial classification of the 194 variants as being of uncertain signifi-
cance was because, prior to our study, they had never been
reported in human reference databases, nor had they been de-
scribed in either clinical cases of disease, nor studied in vitro or
in vivo. However, by detecting 149 of these in control subjects
Table 1. Clinical data for the 1511 brains in this study
Age of onset
(yr)
Age of death
(yr) Female Male FH of disease
Number of cases (n) Age SD Age SD n % n % n %
AD 289 65.5 10.4 77.6 11.6 151 52.2% 138 47.3% 11 3.8%
CBD 14 60.1 11.4 69.6 12.4 4 21.4% 10 61.5% 0 0.0%
CJD 239 52.6 19.9 53.5 19.5 111 46.7% 128 53.3% 4 1.7%
Control 368 63.2 18.8 131 35.5% 237 64.2% 0 0.0%
Control (High Braak) 38 87.6 8 24 63.2% 14 36.8% 0 0.0%
DLB 58 66.7 8.4 76.7 7 22 37.9% 36 62.1% 2 3.4%
FTD-ALS 252 59.5 11.7 64.6 11.6 103 40.9% 149 59.1% 14 5.6%
HD 7 59.8 13.2 66.7 10.3 3 42.9% 4 57.1% 1 14.3%
MSA 10 58.4 6.5 68.2 9.1 1 10.0% 9 90.0% 0 0.0%
Other disorders 80 57.4 25.3 72.4 18.3 35 43.8% 45 56.3% 9 11.3%
PD 39 59.9 10.9 72.3 9.2 11 28.2% 28 71.8% 0 0.0%
PSP 17 68.7 12.1 77.1 10.3 9 52.9% 8 47.1% 0 0.0%
Cerebrovascular disease 65 79.9 8.6 85.7 6.1 32 49.2% 33 50.8% 1 1.5%
Cerebrovascular disease/AD 17 82.5 6.3 84.5 6.6 10 58.8% 7 41.2% 0 0.0%
Vascular disease/control 18 81.2 13.7 89.8 7.2 8 44.4% 10 55.6% 0 0.0%
Total 1511 59.6 17.7 68.3 17.9 655 43.3% 856 56.7% 42 2.8%
All ages are given in years. (AD) Alzheimer’s disease, (CBD) corticobasal degeneration, (CJD) Creutzfeldt-Jakob disease, (DLB) dementia with Lewy
bodies, (FTD-ALS) frontotemporal dementia–amyotrophic lateral sclerosis, (HD) Huntington’s disease, (MSA) multiple system atrophy, (PD) Parkinson’s
disease, (PSP) progressive supranuclear palsy. All cases in which they did not conform to a specific group were included in ‘other.’ (FH) family history.
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or in cases with a discordant phenotype, we were able to con-
clude that they were likely to be benign (Supplemental Table
Clinical data; Supplemental Table Variant data). Forty-five vari-
ants in 52 cases remained classified as being of uncertain signifi-
cance after initial assessment (3.6% of 1461 cases undergoing
exome sequencing), with these variants present in phenotypical-
ly appropriate cases for the genotype or in young control sub-
jects. Over 50% of these variants are entirely novel (n = 23),
having never been previously detected in human subjects not
in any other cases in our data set, nor the three on-line databases
accessed in this study (n = 69,660).
Homozygous or compound heterozygous SNVs, insertions, or
deletions in genes known to cause common neurodegenerative
diseases
Homozygous or compound heterozygous variants known to
cause disease were seen in only four cases and were considered
to be pathogenic (Fig. 1; Supplemental Table Clinical data;
Supplemental Table Variant data).
Single heterozygous SNVs, small insertions, or deletions in genes
known to cause rare neurodegenerative diseases
In 10 cases with rare neurological disorders, pathogenic variants
were detected in three brains: Case 24, adult-onset ganglosidosis
(HEXA; p.R499C); Case 29, Kuf’s disease (DNAJC5; p.L115R);
and Case 44; chorea-acanthocytosis (VPS13A; p.L1841∗/p.
W2347fs∗36) (Fig. 1; Supplemental Table S4; Supplemental Table
Clinical data; Supplemental Table Variant data).
C9orf72 screening
The C9orf72 hexanucleotide repeat expansion was present in 15/
1482 brains cases (1% of the total disease cohort, and 6.14% of
all FTD or ALS cases (n = 244) which had C9orf72 analysis). Of
note, the ‘FTD-ALS’ cohort combined all isolated FTD cases, isolat-
ed MND cases, and FTD-ALS cases into one cohort due to the ge-
netic overlap between these disorders (Supplemental Methods;
Supplemental Table S5). These findings were confirmed by
Southern blot.
Identity By Descent (IBD) analysis
IBD using the SNV genotypes revealed nine pairs of individuals
with cryptic 1st–4th degree ancestry (Supplemental Table S6;
Supplemental Fig. S3). This led to a molecular diagnosis of spino-
cerebellar ataxia (SCA) because one of two first-degree relatives
within the cohort was diagnosed with SCA7 in a parallel study,
leading to the diagnosis in the remaining relative.
Copy number variation
Rare copy number variants (CNVs) spanning the coding region of
any of the 49 common neurodegenerative disease genes included
in our study (see Supplemental Methods for criteria and
Supplemental Table S2 for gene IDs) were seen in 1.46% of cases
(n = 19). Only one CNV occurred in a gene known to convey path-
ogenicity through copy number variation (Case 61: Alzheimer’s
disease with an APP triplication) (Supplemental Table S7) and
was considered to be pathogenic. Copy number gains were also
seen in APOE (n = 1), DAO (n = 1), SCARB2 (n = 1), and SPG11 (n =
1), and copy number loss in LRRK2 (n = 1) and PARK2 (n = 4).
Figure 1. Summary of the molecular genetic approach and the data passing quality control (QC) in 1511 postmortem brains. Algorithm showing the
genotyping strategy and headline positive results.
Genomic compendium of 1511 human brains
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Nine cases showed a copy number gain in PRPH comprising three
different CNVs, with a mean length of 13.8 kb (SD = 0.9 kb) (Fig 4;
Supplemental Table S7). Six of the nine cases had AD, resulting in
PRPH copy number gains having a significant association with AD
vs. all controls with CNV data (n = 383, P = 0.015, Fisher’s exact
test), and when compared to all forms of neurodegenerative dis-
ease (n = 1060, P = 0.002). The three other brains with PRPH copy
number gains showed: pathologically atypical tauopathy with
AD-like features; ALS; and a control case with an age at death
two standard deviations below the mean of the confirmed AD cas-
es with PRPH copy number gains.
Risk factor SNVs
Alleles previously described as conferring a risk of AD, DLB, FTD-
ALS, or PD were identified (Supplemental Table S8), with 38 cases
possessing established risk factors in TREM2, GBA, LRRK2
(Supplemental Table S8). We also compared the total burden of
rare coding variants in genes known to act as risk factors for disease
for each case cohort compared to aged (>55 yr) neuropathologi-
cally normal controls. We confirmed associations between AD
and variants in TREM2 (cases; n = 20 [6.9%], controls n = 8
[3.3%]; P = 0.017), DLB with GBA (cases; n = 8 [13.8%], controls:
n = 10 [4.1%]; P = 0.0075), and TREM2 (cases; n = 7 [12.1%], con-
trols: n = 8 [3.3%]; P = 0.0084), and FTD-ALS with SQSTM1 (cases;
n = 29 [13.2%], controls: n = 16 [6.6%]; P = 0.0076) (Supplemental
Table S8).We also identified a putative novel risk factor for disease:
the TREM2 p.R62H variant with DLB (P = 0.0024, OR;3.2 [95% CI
1.7–27]) which was seen in 7/58 cases (12.1%) and 5/244 controls
(2.05%). We also found supporting evidence that the SQSTM1 p.
P392L variant is a risk factor for FTD-ALS (P = 0.05). APOE∗E3/4 al-
leles and E4/4 alleles were strongly associated with AD (P < 0.0001)
and DLB (P < 0.001) (Supplemental Table S9). In total, 349 cases or
controls had at least one protein-altering variant in a gene previ-
ously associated with an appropriate neurodegenerative disease
(Fig. 2; Supplemental Tables S8, S9).
Genotype-pathology and genotype-clinical correlations
There was no association between the presence of variants in any
risk-factor gene (TREM2,GBA, LRRK2, SQSTM1,GRN) and anyneu-
ropathological assessment score or any clinical parameter (age of
onset, death, or disease duration). When substratifying by disease,
TREM2 variants in AD cases were associated with a shorter disease
duration (Kaplan-MeierMantel-Cox, P = 0.027) (Supplemental Fig.
S4), but there were no other associations between any risk-factor
variants and any clinical or pathological feature.
Novel risk-factor associations
To determine whether variants in any established risk-factor gene
conferred risk for alternative forms of neurodegenerative disease
we performed burden testing of all risk-factor genes across all large
cohorts (AD, FTD-ALS, CJD, DLB) compared to an extended ver-
sion of all controls (n = 380). Cases possessing highly penetrant
pathogenic variants (Fig. 1; Supplemental Table S10), were re-
moved from each group before testing. Variants in GRNwere asso-
ciated with DLB (P = 0.005), with eight variants seen in 12.1% of
Figure 2. Exome sequencing in 1461 postmortem brains. Assessment of heterozygous variants in genes known to cause familial forms of neurodegen-
erative disease. All variants were initially assessed against the American College of Medical Genetics (ACMG) criteria and all evidence relating to pathoge-
nicity was recorded according to the guidelines of MacArthur et al. (2014). Comparing variants to clinical and neuropathological data in their respective
cases enabled a significant refinement of likely pathogenicity and, in particular, an increase in the number of variants likely to be benign, allowing the re-
classification of previous variants considered pathogenic.
Keogh et al.
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patients and only 3.2% of controls, though no single allelewas sig-
nificantly associated with disease (Supplemental Tables S10, S11).
Discussion
Using a multimodal sequencing approach, we have identified
highly penetrant alleles causing disease in 61 individuals (hetero-
zygous alleles n = 40, homozygous or compound heterozygous al-
leles n = 5, C9orf72 hexanucleotide repeat expansion n = 15, and
pathogenic CNV n = 1) at postmortem with clinical and patholog-
ical evidence of neurodegenerative disease and a further 349 indi-
viduals with established protein-coding heterozygous genetic risk
factors for neurodegeneration (Fig. 1). This integrated genomic
and pathological data set provides a unique resource to genetically
stratify human brain tissue research and will ensure that future
work using this tissue resource is not confounded by hitherto un-
known genetic factors. The genetic data is available to all research-
ers, enabling the rapid identification and provision of brain tissue
containing genetic variants which emerge as likely risk factors for
neurodegeneration in future years but are currently not known to
be important.
Using current guidelines (Richards et al. 2015), 62% (n = 194)
of rare variants (MAF < 0.5%) were initially classified as being of
uncertain significance. Just under half of these variants were not
present in international reference databases (n = 95, 48.9%) and
with no previous clinical or functional in vitro modeling to sup-
port or refute pathogenicity (Supplemental Tables Clinical data
and Variant data; MacArthur et al. 2014). However, analysis of
our clinical and pathological data showed that 149 of these 194
variants (76.8%) were found in control brain donors or in patients
with incongruous clinical phenotypes, enabling the reclassifica-
tion of 149 variants as likely to be benign. These findings illustrate
the importance of studying postmortem tissue in late-onset disor-
ders where the clinical phenotype alone may be unreliable.
In addition to the reclassification of uncertain variants as
benign, our data also shows the converse: that specific alleles previ-
ously dismissed as benign, may be pathogenic. For example, the
PSEN2 p.D439A variant was first described in patients with AD
but subsequently found in asymptomatic controls. This led some
to conclude that PSEN2 p.D439A was not pathogenic (Sassi et al.
2014). In this study, we saw PSEN2 p.D439A in both an AD and
a control brain. However, the control brain had moderate
Alzheimer-type pathology (Braak stage 3/4), supporting possible
pathogenicity with age-related penetrance. Our findings therefore
show that the presence of a variant in a clinically defined ‘healthy
control’ isnot reliable, and it isunwise to rejectaputativepathogen-
ic variant as benign without a comprehensive assessment of the
neuropathology in an ostensibly healthy control subject. For neu-
rodegenerative diseases, this means a postmortem examination.
Related to this, another unique and valuable feature of the re-
source is the inclusion of young clinically unaffected controls (n =
135 under age 55). Genotyped control brains provide an opportu-
nity to explore the preclinical effects of neurodegenerative risk al-
leles, before significant cell loss and secondary pathological
Figure 3. Frequency of known pathogenic mutations and risk alleles in 1511 postmortem brains. (A) Number of brains with mutations in known familial
neurodegenerative disease genes, and (B) the nature of pathogenic and likely pathogenic variants in each disease category. (C) Number of brains with a
known genetic risk factor for neurodegenerative disease, and (D) known genetic risk factors in each subgroup (APOE∗E4 alleles excluded but including rare
coding variants). Variants which were significantly associated with each disease cohort are highlighted by an asterisk (P < 0.05, Fisher’s exact test). All var-
iant associations with disease can be seen in Supplemental Tables 7 and 8.
Genomic compendium of 1511 human brains
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change. In this study, this was only seen once, in a young control
harboring a known pathogenic mutation (compound heterozy-
gous PARK2 mutations). Larger cohorts of control brain tissue are
likely to yield more examples and thus provide valuable insight
into the preclinical pathology of late-onset neurological disorders,
potentially revealing early targets for therapeutic intervention.
We also found exceptionally rare genotypes of disease, in-
cluding a homozygous p.R217∗ OPTN mutation and a novel
p.G216R missense variant in HNRNPA1,
both causing ostensibly sporadic cases
of motor neuron disease (Fig. 5). Other
than the original case series (Maruyama
et al. 2010), this is one of only a handful
of known pathogenic homozygous
OPTN cases, and HNRNPA1 variants
have failed to be detected in several large
clinical cohorts (Seelen et al. 2014).
Identification of brain tissue from these
rare forms of disease provides an invalu-
able opportunity to further define the
molecular pathogenesis of these disor-
ders and establish genotype-phenotype
relationships. For example, although
both mutations were associated with a
TDP-43 proteinopathy (Fig. 5), the neu-
ropathological pattern was atypical in
the homozygous p.R217∗ OPTN patient,
demonstrating dominant subcortical
and glial proteinopathy.
Analyzing the coding region vari-
ants across the entire cohort enabled a
compilation of a comprehensive data-
base of genotype-phenotype correlations
and facilitated the detection of rare phe-
notypes and presymptomatic cases of
disease. This is perhaps best highlighted
by the homozygous SOD1 p.D91A vari-
ant, which classically presents with distal
lower motor-neuron features and pro-
gresses slowly (Andersen et al. 1996).
Here, we detected the same homozygous
variants in a patient with atypical de-
mentia and some clinical features over-
lapping with multiple system atrophy
(MSA). In addition, we found a 35-yr-
old clinical control male with a previous-
ly identified pathogenic compound heterozygous mutation in
PARK2. Subsequent repeat neuropathological assessment showed
no evidence of neuronal loss within the substantia nigra. Given
his age at postmortem, it is not clear whether this individual was
presymptomatic, or whether the alleles have a reduced clinical
penetrance in this case. Larger cohorts of neuropathologically
stratified cases are likely to assist in determining pathogenicity in
such cases.
Figure 4. Copy number gain in PRPH. (Upper) q13 region of Chromosome 12 is shown. (Middle)
Individual points show the Log R Ratio (LRR) and beta allele frequency (BAF) of SNV genotyping SNPs
between base position 49640000 and 49740000 on Chromosome 12 (GRCh37 build). Positive LRR val-
ues in the gray shaded region are consistent with a copy number gain in that region (>3 SDs above the
mean of the cohort) (see Supplemental Methods). The PRPH gene within that genomic region is identi-
fied on the x-axis. (Lower) 5′ position of the final SNP in the copy number region in the three different
CNVs identified and their relevant position in the PRPH protein (orange, green, blue), highlighting
that three different CNV end positions were identified in patients within the study within the PRPH gene.
Figure 5. Neuropathology in the brain donors found to harbor anOPTN (A,B) and HNRNPA1mutation (C). (A,B) Severe degeneration with spongiosis of
the primary motor cortex (haematoxylin and eosin, and atypical, predominantly subcortical white matter TDP-43 proteinopathy, A) in the patient with the
OPTNmutation. In contrast, in C, the HNRNPA1mutation was associated with a lower motor neuron phenotype with classical skein-like cytoplasmic mis-
localization of TDP-43 (C, hypoglossal nucleus). (A, 200×; B,C, 400×.) (Cx) Cortex, (SCxWm) subcortical white matter.
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We also made number of novel observations. Firstly, p.R62H
TREM2 variant appears to be a risk factor for DLB (P = 0.0024,
OR;3.2 [95% CI 1.7–27]). This variant was previously reported in
association with AD (Jin et al. 2014), and although these findings
need replication, these observations further emphasize the over-
lapping genetic etiology of DLB and AD and endorse the view
that TREM2 increases the risk of developing several neurodegener-
ative diseases (Rayaprolu et al. 2013). Second, we show the first as-
sociation of GRN variants with DLB. Again, this will require
replication but suggests a novel genetic overlap between DLB
and FTD. Thus, a combination of genetic risk factors contributes
to the prevalence of DLB, which affects ∼5% of those aged over
80 yr but rarely affected more than one individual in a family
(Meeus et al. 2012). Finally, we provide the first evidence of an as-
sociation between a 13.8-kb copy number gain within PRPH and
AD, found in six patients with typical AD pathology (Fig. 4).
Although point mutations have previously been found in associa-
tion with ALS/MND (Gros-Louis et al. 2004), the recent finding
that peripherin may regulate amyloid metabolism (Muresan
et al. 2014) provides a potential mechanism linking amyloid dep-
osition and the first possible overlapping genetic mechanism be-
tween ALS/MND and AD.
There are several explanations for the absence of a relevant
family history in most (73.8%) of the 61 likely genetically deter-
mined cases we identified (n = 45), including early death in previ-
ous generations, incomplete penetrance, de novo mutation, and
false paternity. Although we cannot resolve this issue for individ-
ual cases, our findings do highlight the importance of considering
highly penetrant single gene defects in patients with an ostensibly
sporadic neurodegenerative disease.
Although a number of known genetic causes of neurodegen-
eration were not included in our analysis, including large inser-
tions, deletions, and large-scale inversions, these are only likely
to be relevant for a small minority of cases. In addition, being an
analysis of a legacy collection, newer neuropathological assess-
ment criteria were not available in brains collected some time
ago. However, the fine-detailed genetic characterization of specific
alleles and contemporary histopathological assessments will be
added in the near future. This genetic compendium of 1511 brains
includes 40 brains with highly penetrant SNVs in 13 known dis-
ease genes, five cases with homozygous or heterozygous variants
in four genes, together with pathological expansions of C9orf72
in 15 cases, and a copy number gain of APP in one case, resulting
in a total of 61 cases of genetically determined disease. The com-
pendium also includes 349 cases and aged controls with estab-
lished risk protein coding alleles for neurodegenerative disease
(Fig. 1). The whole data set will facilitate variant interpretation
and provides a framework for the genetic stratification of future
human postmortem analysis studies.
Methods
Clinical and pathological data
Ethical approval for the genetic analysis of postmortem brain tis-
sue was obtained from the ethical review board of each participat-
ing center. One thousand five hundred eleven brains were selected
from four centerswithin theMRCBrain BankNetwork to include a
representative range of neurodegenerative disorders and controls
who died from unrelated causes (Table 1; Supplemental Table
S1). Demographic data (age of disease onset and death, disease
duration, and family history of disease), together with the ante-
mortem clinical diagnosis and postmortem neuropathological
diagnosis were recorded for all cases. Quantitative neuropatholog-
ical scores and stages (e.g., Braak neurofibrillary tangle stage [Braak
et al. 2006]) were also supplied for each case as appropriate (see
Supplemental Methods). For cases conforming to diagnostic crite-
ria for Creutzfeld-Jakob disease (Budka et al. 1995), the clinical sub-
group (sporadic, familial, variant, or iatrogenic) was also recorded.
Antemortem clinical and postmortem pathological data were
reviewed for all 1511 cases to ensure the antemortem history was
consistent with the neuropathological diagnosis for all disorders
(Supplemental Methods). Given the known neuropathological
and genetic overlap, cases with either frontotemporal dementia,
motor neuron disease /amyotrophic lateral sclerosis, were included
in a combined FTD-ALS subgroup. When antemortem symptoms
were either absent or unavailable, the case was categorized as ‘oth-
er,’ alongside rare neurological diagnoses. A full description of the
cohort stratification process togetherwith the specific diagnoses of
rare cases can be found in Supplemental Table S1 and the
Supplemental Methods.
Molecular genetic and bioinformatic analysis
DNA extraction
DNA was extracted from either the cerebellum, cerebral cortex, or
basal ganglia as described in the Supplemental Methods.
Exome sequencing and analysis
Genomic DNA was fragmented, exome enriched, and sequenced
(Nextera Rapid Exome Capture 62 Mb and HiSeq 2000, 100-bp
paired-end reads). Bioinformatic analysis was performed using an
in-house pipeline including alignment (human reference genome
hg19, UCSC) using Burrows-Wheeler Aligner (BWA) (Langmead
et al. 2009). Variant calling was performed using FreeBayes
(Garrison and Marth 2012). Subsequent analysis was restricted to
on-target homozygous, heterozygous, and compound heterozy-
gous variants with aminimum read depth of 10 in any case or con-
trol, and base quality score of 20 within the cohort. Further
analysis was performed on frameshift, in-frame indel, or start/
stop codon change, missense variants, and splice site loss variants
with a minor allele frequency < 0.5% or < 3% (for familial forms of
disease or risk-factor alleles, respectively) in the 1000 Genomes
Project Database (The 1000 Genomes Project Consortium 2012),
European American cases from the NHLBI ESP exomes database
(ExomeVariant Server 2016), and ExAC server (Lek et al. 2016), us-
ing Qiagen Ingenuity Variant Analysis software. Variants in genes
known to cause familial forms of neurodegenerative disease
(Supplemental Methods; Supplemental Table S2) with the appro-
priate inheritance pattern were assessed in all cases according to
both the 2015 American College of Medical Genetics (ACMG)
(Richards et al. 2015) and the MacArthur Criteria (MacArthur
et al. 2014), irrespective of phenotype or neuropathological diag-
nosis (Fig. 2). The ACMG criteria remain the world’s leading crite-
ria for the interpretation of sequencing variants in a clinical
context, and the MacArthur criteria are a second stringent criteria
that propose that researchers summarize and present a spectrumof
evidence in order to truly attribute pathogenicity of identified al-
leles in sequencing studies. The same criteria were also applied to
a specific assessment of a small number of caseswith rare neurolog-
ical diseases, undertaken independently (adult onset gangliosido-
sis, cerebello-olivary atrophy, chorea-acanthocytosis, Huntington-
like disease, Kuf’s disease, infantile onset mitochondrial disease,
neurodegeneration with brain iron accumulation, and primary fa-
milial basal ganglia calcification) (Supplemental Methods;
Supplemental Table S4).
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Associations at the gene level
Initially, known pathogenic and likely pathogenic causes of dis-
easewere removed. Known risk-factor associations at the gene level
were then tested through case burden testing using Sequence
Kernel Association Test (SKAT-O) (Wu et al. 2011) against a group
of control cases aged 55 or over with no features of neurodegener-
ative disease (Supplemental Methods) (n = 244) within Ingenuity
Variant Analysis. Subsequent allele-level associations were as-
sessed through χ2 testing with a Mantel-Haenszel correction
when a count of zero occurred in either group. Subsequent analy-
ses for novel associations between disease cohorts and controls
were performed against an expanded cohort of controls across
the whole age range (n = 380 including n = 244 aged controls,
plus n = 136 young controls and vascular controls) (see
Supplemental Methods).
Array genotyping and analysis
Array genotyping was performed on all samples using the Illumina
HumanOmniExpress-12 BeadChip array (Illumina) and subse-
quently utilized to perform Identity by Descent to determine relat-
ed individuals within the data set. Single nucleotide variant
genotyping data was also used to determine copy number variants
within genes known to cause familial forms of disease or act as
known risk factors (Supplemental Methods). Rare CNVs were de-
fined as those present in <1% of cases in references databases.
Additional allele-specific genotyping
Specific genotyping to determine the APOE genotype was also
performed independently because of poor exome and SNV array
coverage (Supplemental Methods). Screening for the C9orf72 hex-
anucleotide repeat expansion was also performed as described
(Renton et al. 2011). Positive results were confirmed by Southern
blot (Beck et al. 2013), allowing an estimate of the repeat size.
Data access
Clinical, pathological, and genetic data from this study have
been submitted to the European Genome-phenome Archive
(EGA, https://www.ebi.ac.uk/ega/home) under accession number
EGAS00001001599. VCF files and associated and annotated
metadata (clinical and neuropathological diagnosis, age of disease
onset, and age of death) are available for download through this
archive. All requests for data should be made to the Data Access
Committee as identified through the portal. Access to brain tissue
is available through http://www.mrc.ac.uk/research/facilities/
brain-banks/.
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